|Last Update: 05/21/13 - 4:00 PM EDT|
|YTD Performance: -19.04%|
|Previous Close: $15.10|
|52 Week Range: $13.87 - $29.37|
|Oustanding Shares: 49,306,028|
|Market Cap: 740,083,480|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||3||2||5||5|
|Growth Rate (Year over Year)||-141.67%||97.62%||-101.03%||2,155.56%|
AUXL was upgraded from Underweight to Equal-weight, Morgan Stanley said. Risk/reward is more attractive, following a 50% decline since July. $14 price target.
Portfolio Mgr. David Peltier analyzes a volatile, low-dollar drug stock.
Shares of AUXL now seen reaching $29, Jefferies said. Estimates also lowered on Testim miss. Buy rating.
Portfolio David Peltier finds a pharma name that's quietly growing faster than its peers.
Shares of AUXL now seen reaching $32, Jefferies said. Estimates also raised on first quarter results. Buy rating.
Shares of AUXL now seen reaching $32, UBS said. Estimates also increased as Testim sales ramp should drive upside. Buy rating.
AUXL was downgraded to Market Perform, Leerink Swann said. Company lacks near-term catalysts. $25 price target.
Shares of AUXL now seen reaching $30, Jefferies said. Good buying opportunity on positive Peyronie's data. Buy rating.
Portfolio Manager David Peltier uncovers a drugmaker that's pulled back to an attractive level.